No child left behind: Startup snares $60M to target childhood cancers

The company's first drug was initially developed at South San Francisco's Sunesis Pharmaceuticals.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.